Linda J. Burns, MD, on a Phase II Study of ACE-536 in Beta-Thalassemia

2014 ASH Annual Meeting

2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 53, “ACE-536 Increases Hemoglobin and Decreases Transfusion Burden and Serum Ferritin in Adults With Beta-Thalassemia: Preliminary Results From a Phase II Study,” presented by Antonio G. Piga, MD.

Hagop Kantarjian, MD, on Inotuzumab Ozogamicin Plus Low-Intensity Chemotherapy in ALL

Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 794,

Hematologic Malignancies

Keith McCrae, MD

Keith McCrae, MD, on Managing Heparin-Induced Thrombocytopenia

Keith McCrae, MD, of the Cleveland Clinic, offers his thoughts on abstract 4848, “Implementatio...

Lymphoma

Laurie Sehn, MD

Laurie Sehn, MD, on Nivolumab in Patients With Relapsed/Refractory Hodgkin Lymphoma

Laurie Sehn, MD, of the BC Cancer Agency, on abstract 289, “Nivolumab in Patients With Relapsed...

Leukemia

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Progress Made Against AML and APL

James. O Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Richard M. Stone, MD, of the Dana-Farber Cancer Institute, discuss advances ...

Leukemia

Hagop Kantarjian, MD

Hagop Kantarjian, MD, on Treating Philadelphia Chromosome–Positive ALL

Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 797,

Nov

Today In Oncology

Laurie Sehn, MD, on Nivolumab in Patients With Relapsed/Refractory Hodgkin Lymphoma

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Progress Made Against AML and APL

Hagop Kantarjian, MD, on Treating Philadelphia Chromosome–Positive ALL

Breast Cancer Risk and Disease-Causing Genetic Mutations in Women Older Than 65

Prediagnosis and Postdiagnosis Physical Activity and Survival in Endometrial Cancer

Should Patients With a Complete Response to Neoadjuvant Chemoradiation for Rectal Cancer Also Undergo Surgery

Intermittent Dosing Schedules of RAF/MEK Inhibitor in RAS/RAF-Mutant Solid Tumors and Multiple Myeloma

Study Finds Universal Genetic Testing Uncovers More Inherited Mutations vs Guideline-Based Genetic Testing

Linda J. Burns, MD, on a Phase II Study of ACE-536 in Beta-Thalassemia

Related Videos

Hagop Kantarjian, MD, on Inotuzumab Ozogamicin Plus Low-Intensity Chemotherapy in ALL

Keith McCrae, MD, on Managing Heparin-Induced Thrombocytopenia